PetMed Express, Inc.
PETS · Price history
Price at last available close
$1.19
−$0.21 (-15.00%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About PetMed Express, Inc.
Primary reporting period: 2026-03-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines. Their non-prescription offerings include products for flea and tick prevention, joint and bone care, vitamins, treats, nutritional supplements, hygiene essentials, and general pet supplies.
How they make money
PetMed Express operates as a direct-to-consumer pet pharmacy and health platform. The company generates revenue primarily through the sale of prescription and non-prescription pet medications, supplements, and health products, utilizing an e-commerce model supported by AutoShip subscription programs and professional veterinary consultation services.
Products & services
The company offers a range of pet health solutions including prescription medications, generic pharmaceuticals, compounded medications, and over-the-counter supplements and nutrition products for dogs, cats, and horses.
Brands & revenue mix
Primary consumer-facing brand for pet healthcare and pharmacy services.
Separate brand revenue is not available in this research.Source
Wholly owned subsidiary and brand offering pet health solutions.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pet owners (pet parents)Source
Customer concentration
The company does not disclose specific major customers; however, it notes that approximately 62.6% of sales in the fourth quarter ended March 31, 2026, were generated via its AutoShip and membership program.
Suppliers, materials & equipment
- Primary Pharmaceutical Suppliers — The company sources inventory from various manufacturers and distributors, with approximately 88% of inventory spend concentrated among ten primary suppliers.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
27
Poor
Financial Strength
55
Business Quality / Moat
0
Management
40
Growth Quality
8
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
27
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
34/100
Building Historical Record
Model Score 34/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for PETS
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving PETS's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can PETS fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is PETS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for PETS to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PETS's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
27
Market Cap
$25.8M
P/E Ratio
-0.9
EPS
$-1.38
52-Week High
$4.10
52-Week Low
$1.20
Beta
0.84
Analyst Target
$1.40
Shares Outstanding
20.9M
Total Revenue
$168.9M
Total Debt
$414K
Dividend
No current dividend
Liquidation Value / Share
$1.10
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for PETS
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Community Sentiment
0 active · 0 total callsNo personal call yet on PETS.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Licensed pharmacy operations across all 50 states.
- +Established AutoShip subscription and membership platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Specialty Retail industry.
- −Dependence on a limited number of suppliers for inventory.
- −Fluctuations in prescription medication reorder volumes.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
25
Oct 13, 2026
Change
Unchanged
Current Score
25
Oct 15, 2026
Category Changes
PETS score was unchanged.
Projected Score
Projected Score
23
Projected Change
-2.0 points
Preliminary comparable-period financial changes suggest decline of approximately 2.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.19
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $168.9M | $179.0M | $227.0M | $274.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $128.8M | $138.2M | $157.8M | $196.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $40.0M | $40.8M | $69.1M | $77.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $68.7M | $72.2M | $62.4M | $79.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $70.8M | $72.2M | $70.7M | $84.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$21.8M | -$22.0M | $6.7M | $783K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$30.8M | -$31.4M | -$1.5M | -$7.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $443K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$29.3M | -$57.4M | -$587K | -$6.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$69K | -$73K | $5.7M | $1.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$29.3M | -$57.3M | -$6.3M | -$7.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.38 | $-2.74 | $-0.30 | $-0.37 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 21.68M | 20.92M | 20.60M | 20.40M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 21.68M | 20.92M | 20.60M | 20.40M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$41.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.28
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
No material change
Cash Change
No material change
Margin Change
+51.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
Potential Score Impact
Positive indicators included net income margin. Pressure indicators included revenue growth, EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 19.9%. EPS declined 83.0%. Cash was essentially unchanged. Total debt was essentially unchanged. Net income margin improved by 51.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Specialty RetailNews
PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition
PetMeds Appoints Andrew Parry as Chief Technology Officer
Rumor Mill · PETS
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial